MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 4.3% – Here’s Why

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)’s share price traded down 4.3% on Thursday . The stock traded as low as $1.09 and last traded at $1.10. 69,365 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 1,921,606 shares. The stock had previously closed at $1.15.

MIRA Pharmaceuticals Stock Down 3.6 %

The business has a 50-day simple moving average of $1.12 and a 200-day simple moving average of $1.22. The company has a market cap of $17.55 million, a PE ratio of -1.89 and a beta of 2.31.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its earnings results on Friday, March 28th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.14. On average, research analysts forecast that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current fiscal year.

Institutional Trading of MIRA Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of MIRA. Northern Trust Corp lifted its stake in MIRA Pharmaceuticals by 50.9% in the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock valued at $35,000 after buying an additional 10,238 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of MIRA Pharmaceuticals in the fourth quarter worth approximately $28,000. International Assets Investment Management LLC acquired a new stake in MIRA Pharmaceuticals during the 4th quarter worth $29,000. Renaissance Technologies LLC acquired a new position in MIRA Pharmaceuticals during the fourth quarter worth about $52,000. Finally, Virtu Financial LLC acquired a new position in shares of MIRA Pharmaceuticals during the 4th quarter worth approximately $72,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.